{"created":"2021-03-01T06:25:02.606680+00:00","id":20122,"links":{},"metadata":{"_buckets":{"deposit":"8201224b-0409-4321-90fd-b7a3ba03ad34"},"_deposit":{"id":"20122","owners":[],"pid":{"revision_id":0,"type":"depid","value":"20122"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00020122","sets":["453:456","471:537:538:1161"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Urinary Excretion of Guanidinoacetic Acid in Cisplatin Nephropathy"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1993-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"532","bibliographicPageStart":"523","bibliographicVolumeNumber":"107","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"This study was attempted to evaluate the nephrotoxicity of Cisplatin (CDDP) in 10 lung cancer patients by urinary excretion of guanidinoacetic acid (GAA) , which was produced mainly in the renal proximal tubules by transamidination of glycine from arginine. The urine concentration of N-acetyl-β-glucosaminidase (NAG) and β_2-microglobulin (BMG) was also compared with that of GAA. The urine level of GAA, NAG, and BMG (U-GAA, U-NAG, U-BMG) was measured by high performance liquid chromatography (HPLC), enzyme immunoassay, and latex agglutination method respectively. The serum creatinine level had a significant negative correlation with urinary excretion of GAA (r=-0.35, p<0.05). After administration of CDDP, U-GAA decreased significantly on day 0, 3, 7, 10 and 14. Similarly, U-NAG increased on day 3, 7, and U-BMG on day 0, 1. However, these changes were less prominent than that of U-GAA. The further studies of long-term treated 3 cases revealed that U-GAA was a more sensitive marker than U-NAG or U-BMG in CDDP nephropathy. These findings suggest that U-GAA is extremely useful for early detection of CDDP nephropathy.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"124474","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Tasaki, Kazuyuki"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"田崎, 和之"}],"nameIdentifiers":[{"nameIdentifier":"124473","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-16"}],"displaytype":"detail","filename":"107(6)_523-532.pdf","filesize":[{"value":"1.8 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"107(6)_523-532.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/20122/files/107(6)_523-532.pdf"},"version_id":"01565700-74c3-4029-a97e-1ae0e1436ee0"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"GAA","subitem_subject_scheme":"Other"},{"subitem_subject":"NAG","subitem_subject_scheme":"Other"},{"subitem_subject":"BMG","subitem_subject_scheme":"Other"},{"subitem_subject":"CDDP nephropathy","subitem_subject_scheme":"Other"},{"subitem_subject":"グアニジニノ酢酸","subitem_subject_scheme":"Other"},{"subitem_subject":"NAG","subitem_subject_scheme":"Other"},{"subitem_subject":"β_2 ミクログロブリン","subitem_subject_scheme":"Other"},{"subitem_subject":"シスプラチン腎障害","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Cisplatin腎障害における尿中グアニジノ酢酸の動態","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Cisplatin腎障害における尿中グアニジノ酢酸の動態"},{"subitem_title":"Cisplatin腎障害における尿中グアニジノ酢酸の動態","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1161"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-02-03"},"publish_date":"2016-02-03","publish_status":"0","recid":"20122","relation_version_is_last":true,"title":["Cisplatin腎障害における尿中グアニジノ酢酸の動態"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:50:57.467839+00:00"}